APPRAISE-2 Dashes Hope of Adding Anticoagulant to Antiplatelet Therapy in ACS 1

The factor Xa inhibitor apixaban (under joint development by Bristol Myers Squibb and Pfizer as Eliquis) has been the subject of intense interest in recent years, showing great promise for thromboprophylaxis after surgery and for stroke prevention in AF. Some pundits now believe apixaban will become the anticoagulant of choice for the AF indication, although the basis for this is only a press release about the ARISTOTLE trial, which has not yet been presented or published. So far the only major disappointment concerning the drug has been the APPRAISE-2 trial in ACS patients, which was terminated early last November. The results of the trial have now been presented at the International Society on Thrombosis and Haemostasis Congress in Kyoto and published in the New England Journal of Medicine.

APPRAISE-2 (Apixaban for Prevention of Acute Ischemic Events – 2) was a phase 3 trial comparing apixaban to placebo in patients with acute coronary syndrome (ACS) already receiving standard antiplatelet therapy and who had at least 2 additional risk factors for recurrent ischemic events. The trial was stopped early after 7,392 patients had been enrolled (the original plan had been to enroll 10,800 patients) due to an increase in major bleeding events in patients treated with apixaban.

Here are the main results of the trial, after a median followup of 241 days:

Primary endpoint (combined rate of cardiovascular death, MI, or ischemic stroke):

  • 7.5% (279/3705) in the apixaban group versus 7.9% (293/3687) in the placebo group
  • HR with apixaban:0.95, CI 0.80-1.11, p=0.51

Major bleeding:

  • 1.3% (46/3673 in the apixaban group versus 0.5% (18/3642) in the placebo group
  • HR with apixaban: 2.59, CI 1.50-4.46, p=0.001)

The authors write that the results of APPRAISE-2 fail to confirm the hope derived from 3 phase 2 trials suggesting that oral anticoagulants when added to antiplatelet therapy in ACS patients would reduce recurrent events but would not cause a large excess of bleeding complications. The results of APPRAISE-2, they write, “raise doubt about whether meaningful incremental efficacy can be achieved with an acceptable risk of bleeding by combining a long-term oral anticoagulant with both aspirin and a P2Y12-receptor antagonist in patients with coronary disease.”

About these ads

One comment

  1. Pingback: Rivaroxaban Meets Primary Endpoint in ATLAS ACS TIMI 51 « CardioBrief

What do you think?

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s